Our Company

Onc.AI is a privately held digital health company on a mission to radically improve oncology decision making

The Onclara™ platform leverages a market-leading oncology real-world dataset to train best-in-class predictive and prognostic AI models.

Our first product, Onclara™ Evaluate, improves Phase IB/Phase II clinical trial decision-making for leading pharma companies and is FDA-breakthrough designated.

Our second product, Onclara™ IO, predicts response and outcomes for metastatic lung cancer and patients treated with Immunotherapy.